Vemircopan
Small moleculeexperimental
Clinical trial activity
16 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 28, 2017 (NCT05047458)
Timeline
Indications
Mechanism of action
- Complement factor DINHIBITOR
CFD inhibitor
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)c1nn(CC(=O)N2[C@H](C(=O)Nc3nc(Br)ccc3C)C[C@@]3(C)C[C@@H]23)c2ccc(-c3cnc(C)nc3)cc12- Mol. weight
- 602.49 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650325 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06071442 | Phase 1 | Oct 9, 2023 | Alexion |
| NCT05780645 | Phase 1 | Mar 30, 2023 | Alexion |
| NCT05259085 | Phase 1 | Apr 7, 2022 | Alexion |
| NCT05202145 | Phase 1 | Jan 11, 2022 | Alexion |
| NCT05218096 | Phase 2 | Dec 30, 2021 | Alexion |
| NCT05097989 | Phase 2 | Nov 30, 2021 | Alexion |
| NCT04952545 | Phase 1 | Jul 31, 2021 | Alexion |
| NCT04933682 | Phase 1 | Jun 30, 2021 | Alexion |
| NCT04609670 | Phase 1 | Jan 31, 2021 | Alexion, Celerion |
| NCT04623710 | Phase 1 | Jan 31, 2021 | Alexion |
| NCT04660890 | Phase 1 | Dec 31, 2020 | Alexion, Celerion |
| NCT04551586 | Phase 1 | Mar 24, 2020 | Alexion, Celerion |
| NCT04709081 | Phase 1 | Dec 22, 2019 | Alexion, Celerion |
| NCT04170023 | Phase 2 | Dec 1, 2019 | Achillion Pharmaceuticals |
| NCT05047484 | Phase 1 | Jan 7, 2019 | Alexion |
| NCT05047458 | Phase 1 | Nov 28, 2017 | Alexion |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alexion | For profit | 15 | 15 | 2 | 2017 |
| Celerion | For profit | 4 | 0 | 1 | 2019 |
| Achillion Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1